<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500654</url>
  </required_header>
  <id_info>
    <org_study_id>CFUG 476871</org_study_id>
    <nct_id>NCT02500654</nct_id>
  </id_info>
  <brief_title>Regenerative Surgical Treatment of Peri-implantitis</brief_title>
  <official_title>Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catrine Isehed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Gävleborg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if surgical treatment of peri-implantitis with enamel
      matrix derivative (Emdogain®, EMD) will have an additional effect on the healing outcome,
      changes in the peri-implant microflora and on the inflammatory response in the periimplant
      pocket at 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised controlled clinical trial. Recruiting 31 patient with periimplantitis at
      one or more implants in need for surgical treatment.

      Randomisation to test group (EMD) with surgical treatment and additional application of
      enamel matrix derivative (Emdogain®) or surgical treatment alone in the control group
      (non-EMD).

      Treatment of existing periodontitis performed before recruitment. Baseline examination
      including samples of microbiota and peri-implant fluid followed by surgical treatment. Access
      surgery to remove chronic inflammatory tissue and clean the implant surface from biofilm and
      implant stone with hand instrument and ultrasonic device with special tips for implants,
      followed by polishing the implant surface with a gauze, super floss and rinsing with saline.
      Allocation with a performed block randomisation at the stage of surgery, after cleaning of
      implant surface. Application of enamel matrix derivative (Emdogain®) or not, just before
      closure of flap. After surgery rinsing with chlorhexidine 0.2% twice a day in 6 weeks. No
      systemic antibiotic used in this study.

      Supportive care program, including hygiene instructions and professional cleaning
      supragingival at implants and teeth at 2 weeks, 3, 6, 9 and 12 months after treatment.

      Examination with measurements of pocket depth and bone levels at radiographs at baseline just
      before surgery and 12 months and prevalence of bleeding on probing, pus or recession as well
      as full mouth plaque score and full mouth bleeding score at 3, 6, 9 and 12 months.

      Microbial sampling performed with endodontic paper points at baseline and 2 weeks after
      surgery as well 3, 6 and 12 months from implant site with at baseline the deepest pocket.

      Sampling of the peri-implant fluid from the peri-implant pocket at baseline, 3, 6, and 12
      months from implant site with at baseline the deepest pocket.

      Removal of bridges performed to give accessibility at baseline examination/surgery and at 12
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in marginal bone level at dental implant</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in peri-implant microflora incidence and composition</measure>
    <time_frame>2weeks, 3, 6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in peri-implant pocket depth</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sites with bleeding on probing</measure>
    <time_frame>3,6, 9, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sites with bacterial plaque at the implant</measure>
    <time_frame>3,6, 9, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sites with suppuration on probing</measure>
    <time_frame>3,6, 9, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sites with marginal gingival recession</measure>
    <time_frame>3,6, 9, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full mouth plaque score</measure>
    <time_frame>3,6, 9, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full mouth bleeding score</measure>
    <time_frame>3,6, 9, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Failure of Dental Implant Due to Infection</condition>
  <condition>Infection</condition>
  <condition>Inflammation</condition>
  <condition>Peri-implantitis</condition>
  <condition>Bacterial Infections</condition>
  <condition>Bleeding of Subgingival Space</condition>
  <condition>Molecular Sequence Variation</condition>
  <condition>Periodontal Diseases</condition>
  <condition>Mouth Diseases</condition>
  <arm_group>
    <arm_group_label>Surgery and Emdogain®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>access peri-implant surgery with Emdogain® applied after cleaning of implant surface with saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgery alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>access peri-implant surgery and cleaning of implant surface with saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Emdogain®</intervention_name>
    <description>Surgery and Emdogain®</description>
    <arm_group_label>Surgery and Emdogain®</arm_group_label>
    <other_name>enamel matrix derivative</other_name>
    <other_name>enamel matrix proteins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgery alone</intervention_name>
    <description>Surgery alone</description>
    <arm_group_label>Surgery alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  peri-implant angular bone loss ≥3 mm, measured at radiographs

          -  deep pocket ≥5 mm combined with bleeding and/or pus

        Exclusion Criteria:

          -  individuals with uncontrolled diabetes (HbA1c &gt; 7,0%)

          -  individuals where prophylaxis of antibiotic is indicated

          -  medication with prednisolon or other anti-inflammatory drug

          -  medication with gingival hyperplasia known as a side effect

          -  systemic antibiotic intake the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pernilla Lundberg, Assoc. Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Odontology, Division of Molecular Periodontology , Umeå University, Sweden, pernilla.lundberg@umu.se</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sweden</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Derks J, Tomasi C. Peri-implant health and disease. A systematic review of current epidemiology. J Clin Periodontol. 2015 Apr;42 Suppl 16:S158-71. doi: 10.1111/jcpe.12334. Review.</citation>
    <PMID>25495683</PMID>
  </reference>
  <reference>
    <citation>Heitz-Mayfield LJ, Lang NP. Comparative biology of chronic and aggressive periodontitis vs. peri-implantitis. Periodontol 2000. 2010 Jun;53:167-81. doi: 10.1111/j.1600-0757.2010.00348.x. Review.</citation>
    <PMID>20403112</PMID>
  </reference>
  <reference>
    <citation>Maruyama N, Maruyama F, Takeuchi Y, Aikawa C, Izumi Y, Nakagawa I. Intraindividual variation in core microbiota in peri-implantitis and periodontitis. Sci Rep. 2014 Oct 13;4:6602. doi: 10.1038/srep06602.</citation>
    <PMID>25308100</PMID>
  </reference>
  <reference>
    <citation>Basegmez C, Yalcin S, Yalcin F, Ersanli S, Mijiritsky E. Evaluation of periimplant crevicular fluid prostaglandin E2 and matrix metalloproteinase-8 levels from health to periimplant disease status: a prospective study. Implant Dent. 2012 Aug;21(4):306-10. doi: 10.1097/ID.0b013e3182588408.</citation>
    <PMID>22814555</PMID>
  </reference>
  <reference>
    <citation>Carcuac O, Berglundh T. Composition of human peri-implantitis and periodontitis lesions. J Dent Res. 2014 Nov;93(11):1083-8. doi: 10.1177/0022034514551754. Epub 2014 Sep 26.</citation>
    <PMID>25261052</PMID>
  </reference>
  <reference>
    <citation>Holmlund A, Hänström L, Lerner UH. Bone resorbing activity and cytokine levels in gingival crevicular fluid before and after treatment of periodontal disease. J Clin Periodontol. 2004 Jun;31(6):475-82.</citation>
    <PMID>15142219</PMID>
  </reference>
  <reference>
    <citation>Bosshardt DD. Biological mediators and periodontal regeneration: a review of enamel matrix proteins at the cellular and molecular levels. J Clin Periodontol. 2008 Sep;35(8 Suppl):87-105. doi: 10.1111/j.1600-051X.2008.01264.x. Review.</citation>
    <PMID>18724844</PMID>
  </reference>
  <reference>
    <citation>Esposito M, Grusovin MG, Worthington HV. Treatment of peri-implantitis: what interventions are effective? A Cochrane systematic review. Eur J Oral Implantol. 2012;5 Suppl:S21-41. Review.</citation>
    <PMID>22834392</PMID>
  </reference>
  <reference>
    <citation>Casati MZ, Sallum EA, Nociti FH Jr, Caffesse RG, Sallum AW. Enamel matrix derivative and bone healing after guided bone regeneration in dehiscence-type defects around implants. A histomorphometric study in dogs. J Periodontol. 2002 Jul;73(7):789-96.</citation>
    <PMID>12146539</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Region Gävleborg</investigator_affiliation>
    <investigator_full_name>Catrine Isehed</investigator_full_name>
    <investigator_title>DDS, periodontist</investigator_title>
  </responsible_party>
  <keyword>Peri-implantitis</keyword>
  <keyword>Regenerative therapy</keyword>
  <keyword>Surgical therapy</keyword>
  <keyword>Enamel matrix derivative</keyword>
  <keyword>Peri-implant microflora</keyword>
  <keyword>Peri-implant fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
    <mesh_term>Peri-Implantitis</mesh_term>
    <mesh_term>Mouth Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

